RYTM Stock — Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, Inc. (RYTM)

Updated October 16, 2026.

RYTM is a Stock. Total return is 187.2% over the past 9 years, 56.8 points behind SPY at 244.0%.

Rhythm Pharmaceuticals is a biopharmaceutical company developing treatments for rare neuroendocrine and metabolic diseases, with its lead candidate IMCIVREE (setmelanotide) approved for rare genetic obesity disorders and in clinical trials for additional obesity-related conditions; the company also has earlier-stage programs in development for other melanocortin-4 receptor pathway diseases. The company does not currently distribute to shareholders. This stock appeals to investors seeking exposure to clinical-stage and commercial-stage biopharmaceutical development with a focus on rare disease treatment.

RYTM performance versus SPY

Price and return data through 2026-10-16.

Total return is 187.2% over the past 9 years, 56.8 points behind SPY at 244.0%. Over the past year its total return — price change plus distributions reinvested — is -22.5%. Its deepest 1-year drawdown was 35.5%.

RYTM key facts

Asset type

Stock

Asset class

Equity

Inception date

10/05/2017

Distribution frequency

None

Last close

$86.17 (as of 2026-10-16)

Market cap

$5,932,983,906

Average volume

364054.0

Beta

2.009

Payout ratio

0.0%

Forward P/E

526.3158

EPS

$-3.12

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

RYTM risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 35.5%.

Who may consider RYTM — and who may not

It is a weaker fit for investors who need monthly cash flow (RYTM does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on RYTM

• All tickers starting with R

Tagged: Healthcare.

Frequently asked questions